Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834660 | 0.92 | SLC6A3 (0.41) | SLC6A3SLC6A2ACHESLC6A4ALDH1A1 | |
| SCHEMBL22335527 | 0.90 | SLC6A2 (0.40) | SLC6A3SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL22325047 | 0.83 | BCL2L1 (0.34) | SLC6A3SLC6A2ACHEBCL2 | |
| SCHEMBL30857548 | 0.83 | BCL2L1 (0.34) | SLC6A3SLC6A2ACHEBCL2 | |
| SCHEMBL22335513 | 0.78 | STAT3 (0.30) | — | |
| SCHEMBL1114114 | 0.78 | SLC6A3 (0.63) | SLC6A3SLC6A2SLC6A4BCL2 | |
| SCHEMBL31759009 | 0.78 | PTGS2 (0.35) | SLC6A3BCL2 | |
| SCHEMBL31759015 | 0.77 | BCL2L1 (0.48) | BCL2 | |
| SCHEMBL22325333 | 0.76 | SLC6A3 (0.60) | SLC6A3SLC6A2ACHESLC6A4 | |
| SCHEMBL30857682 | 0.75 | SLC6A3 (0.63) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169628-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220169628-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-06-02 | — | — | US | disclosed |
| EP-3920923-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | University of Florida Research Foundation, Incorporated (US) | 2021-12-15 | — | — | EP | disclosed |
| CN-113660937-A | Therapeutic agents and methods of treatment | 佛罗里达大学研究基金公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2020163823-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163823-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169628-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | HDGF, NFATC1, HGF | SLC6A3 3418/4885SLC6A2 2578/4885ACHE 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.